Lecanemab is a popular Japanese and American medicine, which is a treatment for Alzheimer’s disease. Lecanemab is a humanized version of a mouse antibody mAb158, which finds protofibrils and prevents amyloid beta deposition in animal models of Alzheimer’s disease. On September 27, 2022, Tokyo and Cambridge, Massachusetts PRNewswire/ — Eisai Co., Ltd., whose Headquarters are located in Tokyo, and the CEO is Haruo Naito, “Eisai” and Biogen Inc.

Lecanemab
Lecanemab

Nasdaq: BIIB, Corporate headquarters located in Cambridge, Massachusetts, whose CEO is Michel Vounatsos, “Biogen” has announced the topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody for mild cognitive impairment’s (MCI) treatment. Which affects due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain.

Lecanemab Alzheimer’s Cure

The success of experimental Alzheimer’s medicine is hailed as a ‘historic moment’ and the Study shows reason in early-stage patients on lecanemab declines by 27% less than those on placebo. Now Eisai is looking to file for traditional approval in the United States, and also to submit marketing authorization applications in Japan and Europe by the end of Eisai fy2022, which ends on march 31, 2023.

Lecanemab Alzheimer’s Treatment

Lecanemab is a Monoclonal antibody medicine and Lecanemab is a Whole antibody Type one. Lecanemab Source is Humanized and the target is Beta amyloid. Lecanemab’s scientific name is BAN2401 and the ATC code is none. Lecanemab’s Legal status is Investigational and CAS Number is 1260393-98-3 and DrugBank’s number is DB14580. Lecanemab’s ChemSpider is yet to be updated. Lecanemab’s UNII number is 12PYH0FTU9 and the KEGG number is D11678.

Lecanemab’s All Key Secondary Endpoints Also Met, Demonstrating Highly Statistically Significant Results and the Profile Of Amyloid-related Imaging Abnormalities (Aria) Incidence Was Within Expectations. As per reports, Lecanemab is very effective against Alzheimer’s disease.

Leave a Reply